Cowen and BMO were bookrunners; Canaccord, Needham, Wedbush assisted
By Devika Patel
Knoxville, Tenn., Sept. 6 - Regado Biosciences, Inc. said the underwriters for its initial public sale of stock opted to exercise the deal's $3.7 million greenshoe in part for total proceeds of $46.69 million. The deal was announced April 29 and priced for $43 million with the greenshoe on Aug. 22.
The company sold 11,671,500 common shares at $4.00 apiece. Of the shares, 921,500 were part of the partially exercised greenshoe.
Cowen and Co. and BMO Capital Markets were the joint bookrunning managers.
Proceeds will be used for the REGULATE-PCI trial, working capital and to support operations.
The biopharmaceutical company is based in Basking Ridge, N.J. Its shares trade on the Nasdaq under the symbol "RGDO."
| Issuer: | Regado Biosciences, Inc.
|
| Issue: | Common stock
|
| Amount: | $46,686,000 (including $3,686,000 greenshoe exercise)
|
| Shares: | 11,671,500
|
| Price: | $4.00
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co. and BMO Capital Markets
|
| Co-managers: | Canaccord Genuity, Needham & Co. and Wedbush PacGrow Life Sciences
|
| Announcement date: | April 29
|
| Pricing date: | Aug. 22
|
| Settlement date: | Sept. 6
|
| Stock exchange: | Nasdaq: RGDO
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
